Re-read LEO's 12/31 PR . . . all the news is positive. First cohort on third dose, second cohort on 2x dosage . . . samples taken for analysis . . . news to be reported soon (paraphrased). CTIX is dealing with Dana Farber and cannot release PR's at a whim. This is a clinical study . . . selling now would be severely shortsighted in my opinion.